Viewing nowDizanthin 160 mg (Valsartan)
Valsartan 160mg
Tablet · Prescription medication
Korea United Pharmaceutical Co., Ltd.

MFDS item code 201104797 · Notified 2011.07.29 · Insurance code 644308210
Treatment of essential hypertension and heart failure, and reduction of the risk of death after myocardial infarction
This medication is used to treat essential hypertension and also helps to improve symptoms in heart failure patients who cannot take ACE inhibitors. Furthermore, it has been shown to reduce the risk of death in patients with reduced left ventricular function after myocardial infarction. Therefore, it is used for hypertension management and the treatment of heart failure and after myocardial infarction.
* 40, 80, 160 mg 1. Essential hypertension Take with water during a meal or between meals. It is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). 1) Adults: Regardless of sex or race, oral administration of 80 mg of valsartan once daily is recommended. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be coadministered. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg once daily. 2) Elderly patients (75 years and older): Initiate treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is required. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with reduced intravascular volume: In patients with reduced intravascular volume (e.g., patients taking high-dose diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily, and do not exceed 80 mg once daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily; the dose may be increased to 80 mg or 160 mg per dose. When coadministered with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily, followed over several weeks by dose increases, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is required for a creatinine clearance of 10 mL/min or more. However, do not administer this medicine to patients with a creatinine clearance below 10 mL/min or to patients on dialysis, because there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more per day, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
The safety and efficacy have not been established in children and adolescents under 18 years of age. The safety and efficacy have not been established in children and adolescents under 18 years of age.
This medication can cause serious harm to the fetus when taken during pregnancy, especially in the second and third trimesters, so it must be discontinued immediately upon confirmation of pregnancy. Pregnant or breastfeeding women, and women with a possibility of becoming pregnant, should not take this medication. Patients with severe liver or kidney impairment, those with specific liver diseases, and those with a history of angioedema should not use this medication. Elderly patients or those with hyperkalemia, mild to moderate liver impairment, etc., should take this medication with special caution, and dosage adjustments may be necessary. This medication can cause a rapid drop in blood pressure; therefore, when starting the medication or increasing the dosage, patients should be aware of symptoms of hypotension, especially those with low sodium or fluid volume. Side effects such as headache, dizziness, fatigue, cough, and diarrhea may occur, and in rare cases, serious allergic reactions or renal impairment may occur. Regularly check kidney function and serum electrolyte levels; if abnormalities occur, consult a physician immediately. Interactions may occur when taken with other antihypertensives, diuretics, or potassium-sparing diuretics, so it is crucial to inform healthcare professionals before taking. Caution is advised when driving or operating machinery as dizziness or drowsiness may be experienced. In case of overdose, severe hypotension and shock may occur, requiring immediate emergency treatment. Safety and efficacy in children and adolescents have not been established; hence, use is not recommended. Store in a place out of reach of children and do not transfer to another container.
headache
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air and moisture, and stored in a cool place below 30 degrees Celsius.
Pale yellow-brown elliptical film-coated tablet
For domestic use: 30 tablets/bottle For export: 98 tablets (14 tablets/PTPx7)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowValsartan 160mg
Tablet · Prescription medication
Korea United Pharmaceutical Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.